Navigation Links
FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
Date:3/3/2008

BOSTON, March 3 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I safety results for CardioPET, the company's lead product.

The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with Coronary Artery Disease (CAD). Dr. David Elmaleh, Chairman and scientific founder of FluoroPharma, presented findings from the Phase I trial at the "Clinical Trials Update" session at a Society of Nuclear Medicine conference in Denver, CO.

CardioPET is a novel metabolic cardiac PET imaging agent that allows assessment of acute and chronic coronary artery disease while patients are at rest. FluoroPharma anticipates that CardioPET may be an accurate alternative to standard treadmill stress-testing and for patients that are unable to exercise.

"The CardioPET trial achieved all safety endpoints and experienced no safety issues," said Alan J. Fischman, MD, PhD, Principal Investigator of the CardioPET study. "CardioPET performed well in both healthy volunteers and patients with CAD." Dr. Fischman is a Professor of Radiology at Harvard Medical School and the former Director of Nuclear Medicine at Massachusetts General Hospital.

H. William Strauss, MD, the trial's medical monitor, was also optimistic about CardioPET's potential. "The promise of utilizing PET imaging with a fatty acid analog such as CardioPET to assess integrity of the heart encompasses a wide range of potential indications, and we look forward to validating CardioPET's continued safety in Phase II clinical trials. The PET technology we are studying today shows early promise and may hold the key to better quality CAD diagnoses." Dr. Strauss is the Clinical Director of Nuclear Medicine at Memorial Sloan Kettering Cancer Center and Professor of Radiology at Corne
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today ... Heaton to the Board of Directors. QMC also announced formation ... , QMC Chief Science Officer and Board of Directors Member, along ... Rice University and Mr. Tomio Gotoh , a pioneer of ... " Quantum Materials welcomes two new outside Board members, ...
(Date:7/22/2014)... , July 22, 2014 ... and device company focused on solid dose formulations ... novel solid formulation of octreotide acetate achieved successful ... with the currently marketed liquid product (Sandostatin®).  Based ... the formulation production process to a contract manufacturing ...
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a ... supplements , will celebrate its first anniversary in August. ... is designed to enhance the body,s ability to produce ... that is made up of a variety of phytonutrients ... have been found to increase nitric oxide ...
Breaking Medicine Technology:Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
(Date:7/22/2014)... American Society of Hematology (ASH) will present the Society,s ... Lifetime Achievement in Hematology, to Kanti R. Rai, MD, ... of Medicine for his 50-year career combining landmark clinical ... exceptional patient care. , The Wallace H. Coulter ... an individual who has been a vital contributor to ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... 27 Ten Big Brothers Big Sisters agencies will receive ... "engaging parents as partners" to help children improve their odds ... Sisters is the nation,s largest donor-supported volunteer mentoring network with ... incarcerated parents, with a focus on breaking negative cycles. ...
... , , ISELIN, N.J., Aug. 27 ... for PharmSep: LCGC,s Symposium for Separation Scientists in Pharmaceuticals. The ... DeLand, Pharmaceutical Market Development Manager, Dionex Corporation , and ... will take place in Philadelphia, PA, on September 21-22, 2009. ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... organization has signed a Master Services Agreement (MSA) to use ... Thorough QT (TQT) and Phase 1 studies delivered by its ...
... Dr. ... win the battle against the epidemic of untreated sleep apnea by offering special incentives to ... ... Southern California sleep apnea expert, has found a way to help patients win the battle ...
... ... Announcing an exciting innovation in antimicrobial coatings: OxiTitan VLR. The ... power of light. Durable and easily applied to existing interior surfaces ... utilizing normal incandescent or flourescent lighting. The continuously active photocatalyst traps ...
... ... reduce operating costs and improve efficiencies for homecare providers. , ... (Vocus) August 27, ... improve productivity for homecare providers., , , , ,According to Spencer Kay, President ...
Cached Medicine News:Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 2Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 3Health News:LCGC Announces the Agenda for Their Upcoming PharmSep Conference 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 3Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 4Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 2Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 3Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 2Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 3Health News:New Fastrack Technology Improves Productivity 2Health News:New Fastrack Technology Improves Productivity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: